List of Excipients in Branded Drug AKLIEF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Galderma Laboratories LP	AKLIEF	trifarotene	0299-5935	ACRYLIC ACID/SODIUM ACRYLATE COPOLYMER	2031-07-19
Galderma Laboratories LP	AKLIEF	trifarotene	0299-5935	ALCOHOL	2031-07-19
Galderma Laboratories LP	AKLIEF	trifarotene	0299-5935	ALLANTOIN	2031-07-19
Galderma Laboratories LP	AKLIEF	trifarotene	0299-5935	CYCLOMETHICONE 5	2031-07-19

AKLIEF Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

AKLIEF is a prescription topical acne product containing trifarotene 0.005% in a cream formulation. Its excipient system is commercially relevant because trifarotene is a potent, highly lipophilic retinoid used across large facial and truncal treatment areas. The formulation must balance solubilization, spreadability, preservative protection, skin tolerability, photostability, and manufacturing cost.

The main commercial opportunities are generic or follow-on formulations that improve irritation, packaging, application efficiency, storage stability, and large-area use without changing the active ingredient or strength.

What is AKLIEF and what excipients does it contain?

AKLIEF Cream contains trifarotene 0.005%, equivalent to 50 micrograms per gram. It is approved for the topical treatment of acne vulgaris in patients aged 9 years and older. The labeled dosing regimen is once daily in a thin layer to affected areas of the face and/or trunk (FDA, 2024a).

The FDA-listed inactive ingredients are:

Excipient	Likely formulation role
Dimethyl isosorbide	Solvent and penetration-supporting vehicle
Medium-chain triglycerides	Oil-phase emollient and solvent vehicle
Phenoxyethanol	Preservative
Propylene glycol	Cosolvent, humectant, and penetration enhancer
Sodium edetate	Chelating agent that supports preservative and stability performance
Tocopherol	Antioxidant for the oil phase

The product is supplied as a cream in a tube. The label does not identify the precise manufacturing process, particle-size distribution, microstructure, rheology profile, or quantitative concentration of each excipient (FDA, 2024a).

Why the excipient system matters

Trifarotene belongs to the retinoid class, where irritation, dryness, erythema, peeling, and burning can affect treatment persistence. AKLIEF labeling includes warnings for local irritation and photosensitivity. The vehicle therefore has a direct commercial effect on adherence and prescribing confidence.

Dimethyl isosorbide and propylene glycol likely help maintain trifarotene in a usable dissolved or partially dissolved state. Medium-chain triglycerides provide an oil phase with a relatively light skin feel. Tocopherol can limit oxidative degradation of susceptible formulation components. Sodium edetate reduces the catalytic impact of trace metals, while phenoxyethanol supplies antimicrobial protection.

How does the AKLIEF formulation compare with conventional topical retinoids?

AKLIEF differs from older topical retinoids because trifarotene was developed as a selective retinoic acid receptor gamma agonist. The product is positioned for both facial and truncal acne, expanding the treated surface area beyond the face-only use common in many topical acne regimens (Galderma, 2019).

Product	Active ingredient	Typical dosage form	Key excipient-commercial issue
AKLIEF	Trifarotene 0.005%	Cream	Large-area tolerability and low-irritation vehicle
RETIN-A	Tretinoin	Cream, gel, microsphere gel	Multiple generic vehicle strategies
Differin	Adapalene	Gel, cream, lotion	High generic competition and differentiated tolerability profiles
Tazarotene products	Tazarotene	Cream, gel, foam, lotion	Vehicle design has been used to address irritation and spreadability
Epiduo products	Adapalene plus benzoyl peroxide	Gel	Combination stability and packaging control

A generic trifarotene developer would not need to copy every inactive ingredient. Under the U.S. abbreviated new drug application pathway, the applicant would need to demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for the proposed product. Changes to excipients may trigger comparative characterization, in vitro release testing, clinical endpoint studies, or other evidence depending on the formulation and regulatory pathway.

What excipient strategies could improve AKLIEF?

1. Lower-irritation vehicle design

The most direct opportunity is to reduce local irritation while preserving trifarotene delivery. Potential approaches include:

• Lowering the concentration of propylene glycol if penetration enhancement contributes to burning or stinging.
• Replacing part of the solvent system with a less irritating ester or glyceryl-based vehicle.
• Using a lamellar emulsion to reduce rapid active release at the skin surface.
• Improving water retention through controlled humectancy rather than high solvent loading.
• Adding barrier-supportive lipids, provided they do not alter product classification or create excessive comedogenicity.

The clinical value would be higher treatment persistence and greater use on the trunk, where patients may need treatment over a large surface area.

2. Alternative solubilization systems

Dimethyl isosorbide is effective as a solvent but can be associated with sensory or irritation concerns in some topical products. A follow-on formulation could evaluate:

• Diethylene glycol monoethyl ether.
• Ethoxydiglycol.
• Propylene carbonate.
• Caprylic/capric triglyceride systems.
• Isopropyl myristate or related ester systems.
• Oil-in-water or water-in-oil emulsion architectures.

Each substitute creates technical risks. Trifarotene must remain chemically stable, uniformly distributed, and available for delivery from the vehicle. A less aggressive solvent may improve tolerability but reduce release or penetration.

3. Preservative and preservative-free strategies

The marketed product uses phenoxyethanol. A commercial competitor could pursue:

• A phenoxyethanol-free preserved formulation.
• A lower-preservative system supported by packaging and water-activity controls.
• An airless pump or metered-dose container.
• A single-use or limited-use package for sensitive skin.
• A preservative-free anhydrous formulation.

Preservative-free designs may command a premium in dermatology if they reduce stinging or contact sensitivity. They also increase manufacturing and packaging costs and require strong microbial-control validation.

4. Packaging as part of the excipient strategy

Packaging can improve product performance without changing the active formulation. Relevant options include:

• Airless pump packaging to reduce oxygen and repeated environmental exposure.
• Metered-dose delivery to reduce overapplication.
• Larger-format packaging for truncal acne.
• Unit-dose sachets for samples, travel, and adherence programs.
• Tamper-evident and child-resistant packaging.
• Packaging that improves dispensing of a low-viscosity cream.

The current labeled maximum daily amount is relevant to commercial design. Patients treating both face and trunk may use up to approximately 2 grams daily, making a 45-gram tube a relatively short-course package for extensive disease (FDA, 2024a).

What formulations are protected by AKLIEF-related intellectual property?

The commercial product is associated with Galderma and the trifarotene active ingredient. Intellectual-property risk can extend beyond the active compound to:

• Trifarotene compositions.
• Specific cream vehicles.
• Concentration ranges.
• Solvent combinations.
• Treatment of facial acne.
• Treatment of truncal acne.
• Pediatric acne treatment.
• Manufacturing methods.
• Particle-size and dispersion controls.
• Packaging or stability systems.

A generic applicant may design around a listed formulation patent by replacing one or more excipients, changing the emulsion structure, or using a different manufacturing process. That strategy does not eliminate risk if broader composition, use, or process claims remain in force.

FDA labeling and product databases do not provide a complete freedom-to-operate analysis. Orange Book listings primarily identify patents and regulatory exclusivities submitted for approved drug products. They do not capture every potentially relevant patent, including certain process, formulation, foreign, or unlisted patent rights.

What is the FDA and Orange Book status of AKLIEF?

AKLIEF was approved by FDA in October 2019 for acne vulgaris in patients aged 9 years and older (FDA, 2019). It is a small-molecule topical drug, not a biologic, so biosimilar approval pathways do not apply.

Regulatory element	AKLIEF status
Active ingredient	Trifarotene
Strength	0.005%
Dosage form	Topical cream
U.S. approval	2019
Indication	Acne vulgaris
Minimum labeled age	9 years
Administration	Once daily
Geographic regulatory focus	United States, with international approvals and registrations subject to local rules
Biosimilar pathway	Not applicable
Generic pathway	Potentially ANDA, subject to FDA requirements

Paragraph IV risk would arise if an ANDA applicant certifies that relevant listed patents are invalid, unenforceable, or not infringed. The resulting dispute could involve the active ingredient, cream formulation, method of use, or manufacturing claims. A Paragraph IV certification may trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework, depending on the timing and statutory conditions.

When does AKLIEF lose exclusivity?

AKLIEF’s market exclusivity cannot be reduced to a single date because regulatory exclusivity and patent protection operate separately.

Potential exclusivity layers include:

1. FDA regulatory exclusivity tied to the 2019 approval.
2. Patent protection for trifarotene, formulation, use, or manufacturing.
3. Pediatric exclusivity, if granted and applicable.
4. Patent-term adjustment or patent-term extension.
5. Litigation-related launch constraints.
6. Settlement agreements with generic applicants.

The five-year new chemical entity exclusivity period associated with a qualifying new active ingredient would generally run from approval, subject to statutory rules and the drug’s regulatory classification. A product approved in 2019 could therefore have had a basic NCE exclusivity period ending around 2024, but that does not determine generic launch timing because patent rights may extend beyond regulatory exclusivity.

An accurate launch forecast requires the current Orange Book patent listings, patent-family review, terminal-disclaimer analysis, prosecution history, and any litigation or settlement records. Product-level revenue exposure also depends on whether generic entry occurs before or after the main commercial patent expiry.

Which companies are challenging AKLIEF?

There is no broad public record of a major U.S. generic launch for trifarotene cream comparable to mature tretinoin or adapalene markets. The likely competitive field includes:

• Large generic dermatology manufacturers.
• Specialty generic companies with topical formulation capabilities.
• Contract development and manufacturing organizations.
• Branded dermatology companies pursuing lifecycle products.
• International manufacturers developing non-U.S. trifarotene products.

The strongest potential challengers would have experience with topical creams, in vitro release testing, dermatology endpoint studies, and complex formulation equivalence. Trifarotene is a more specialized target than established generic retinoids because the product has a newer active ingredient and a narrower commercial history.

What commercial opportunities exist for AKLIEF excipients?

Generic substitution

The largest opportunity is a lower-cost generic cream after relevant patent and regulatory barriers no longer block approval. A successful applicant could compete through:

• Lower manufacturing cost.
• Retail and specialty-pharmacy distribution.
• Formulary contracting.
• Larger tube sizes.
• Authorized-generic arrangements.
• Alternative excipient systems that preserve equivalence while reducing raw-material cost.

Premium follow-on topical products

A differentiated formulation could target patients who discontinue standard retinoids because of irritation. Potential positioning includes:

• Sensitive-skin trifarotene.
• Preservative-free trifarotene.
• Fragrance-free and low-sensitizer formulation.
• Rapid-absorbing vehicle.
• Non-greasy truncal-acne product.
• Pump-delivered large-area formulation.
• Pediatric-friendly presentation.

These products would face regulatory and patent constraints if they rely on the same active ingredient and indication. They may also require new clinical evidence if the formulation change affects safety or efficacy.

Combination products

Trifarotene could be combined with other acne therapies, including benzoyl peroxide, topical antibiotics, azelaic acid, or moisturization systems. Combination development faces compatibility challenges:

• Oxidative degradation.
• pH incompatibility.
• Preservative interactions.
• Irritation stacking.
• Packaging limitations.
• Separate-use labeling requirements.

A dual-chamber package or coordinated regimen kit may be more practical than a single homogeneous formulation.

International licensing

Licensing opportunities may involve regional rights, local manufacturing, or formulation technology rather than global rights to the active ingredient. Attractive partners would have:

• Dermatology sales infrastructure.
• Local registration expertise.
• Topical manufacturing capacity.
• Access to public reimbursement systems.
• Experience with pediatric products.

International patent and regulatory positions may differ materially from the United States. A formulation license can retain value after U.S. patent expiry if it supports differentiated products in markets with weaker generic substitution or stronger branded dermatology channels.

How strong is the AKLIEF formulation opportunity?

The formulation opportunity is commercially meaningful but technically demanding.

Factor	Assessment
Active ingredient differentiation	High relative to older generic retinoids
Excipients as a source of product differentiation	Moderate to high
Formulation-development complexity	Moderate
Irritation-management value	High
Packaging opportunity	Moderate
Generic price competition	Likely high after entry
Biosimilar relevance	None
Truncal-acne commercial potential	High
Patent design-around potential	Case-specific
Product-level revenue transparency	Limited because Galderma does not publicly report AKLIEF sales as a separate line item

The most defensible commercial strategy is a vehicle that improves tolerability and dosing convenience for facial and truncal acne. A simple excipient substitution is less likely to create durable differentiation unless it produces measurable benefits in irritation, release, stability, or adherence.

What generic launch scenarios exist for AKLIEF?

Scenario 1: Single generic cream

A conventional generic cream enters after key patent barriers expire or are resolved. Price erosion would likely be rapid because acne treatments are heavily exposed to pharmacy substitution and insurer formulary controls.

Scenario 2: Litigation-delayed entry

An ANDA applicant files a Paragraph IV certification, the innovator initiates litigation, and launch is delayed until settlement, judgment, or patent expiry. The first entrant may receive commercial advantages if it obtains an agreed launch date before later applicants.

Scenario 3: Multiple generic entrants

Several applicants reach approval around the same period. This would compress margins and reduce the value of minor excipient differences.

Scenario 4: Premium differentiated generic

A company launches a formulation with improved sensory properties, larger-area dosing, or preservative reduction. The product may avoid direct commodity pricing but could require additional clinical or comparative evidence.

Key Takeaways

• AKLIEF contains trifarotene 0.005% in a cream with dimethyl isosorbide, medium-chain triglycerides, phenoxyethanol, propylene glycol, sodium edetate, and tocopherol.
• The principal excipient opportunity is irritation reduction without compromising trifarotene release, uniformity, stability, or skin penetration.
• Dimethyl isosorbide and propylene glycol are the most commercially relevant components for solvent and delivery-system redesign.
• Preservative-free systems, airless pumps, metered dosing, and larger truncal-acne packages offer potential differentiation.
• AKLIEF is a small-molecule topical product. Biosimilar competition does not apply.
• Generic risk will depend on Orange Book patents, non-listed formulation and process patents, Paragraph IV filings, litigation, and settlement terms.
• Galderma does not publicly disclose AKLIEF product-level revenue, limiting precise revenue-exposure estimates.
• The strongest follow-on opportunity is a lower-irritation, large-area topical trifarotene product rather than a basic copy of the existing cream.

FAQs

Can AKLIEF excipients be replaced in a generic product?

Yes. A generic applicant may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, performance, safety, and bioequivalence or other applicable evidence standards.

Is dimethyl isosorbide essential to AKLIEF?

The FDA label identifies dimethyl isosorbide as an inactive ingredient, but the label does not establish that it is indispensable. A competing formulation could use another solvent system if trifarotene stability and delivery remain acceptable.

Could a preservative-free trifarotene product compete with AKLIEF?

Yes. A preservative-free formulation could target patients with sensitivity to preservatives or improve positioning in dermatology, but it would require appropriate microbial-control, stability, packaging, and regulatory evidence.

Does truncal acne expand the market opportunity for trifarotene?

Yes. AKLIEF is labeled for facial and truncal acne, creating demand for formulations that spread efficiently, dispense larger quantities, minimize residue, and support treatment over extensive body areas.

Can trifarotene be developed as an over-the-counter product?

A switch from prescription to over-the-counter status would require FDA review of the active ingredient, labeling, safety, consumer comprehension, and conditions of use. AKLIEF’s current U.S. status is prescription-only.

References

1. U.S. Food and Drug Administration. (2019). FDA approves new treatment for acne. FDA.

2. U.S. Food and Drug Administration. (2024a). AKLIEF (trifarotene) cream, 0.005% prescribing information. Galderma Laboratories, L.P.

3. U.S. Food and Drug Administration. (2024b). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

4. Galderma. (2019). AKLIEF Cream prescribing information and product information. Galderma Laboratories, L.P.

5. U.S. Food and Drug Administration. (2024c). Approved drug product and drug exclusivity databases. FDA.